Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Open Access
- 28 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (15), 3887-3900
- https://doi.org/10.1158/1078-0432.ccr-09-3100
Abstract
Purpose: Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy that is dependent on both tumor context and treatment duration. We aimed to characterize this activity and to evaluate the effects of discontinuation of treatment on the dynamics of tumor regrowth.Keywords
Other Versions
This publication has 44 references indexed in Scilit:
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesisNature, 2008
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- The use of GEM models for experimental cancer therapeuticsDisease Models & Mechanisms, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progressionProceedings of the National Academy of Sciences of the United States of America, 2008
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJCI Insight, 2006
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971